Faculty Opinions recommendation of Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Background and Objective: Altered inflammatory response characterizes chronic immunemediated inflammatory diseases (IMID) such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, and psoriasis. Accumulating evidence indicates that regular consumption of extra virgin olive oil (EVOO), the main source of fat in the Mediterranean diet, is associated with a reduced risk of developing chronic degenerative disorders such as cardiovascular diseases, type 2 diabetes and cancer. The beneficial effects on health of EVOO have been attributed, besides to the monounsaturated fats content, to the presence of phenolic compounds that have antioxidant, anti-inflammatory and immunomodulatory properties. The purpose of this review is to provide an overview of the effects of EVOO polyphenols on IMID highlighting the potential mechanisms of action. Methods: Scientific papers were found by searching in PubMed up to May 2017 using the following key words: rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, and psoriasis also in combination with EVOO, phenolic compounds, oleuropein, oleocantal, hydroxytyrosol,tyrosol and oleochantal. Results: In vitro and in vivo studies indicate that EVOO and its polyphenols can improve diseases symptoms in IMID, by acting both at local and systemic levels and by modulating several molecular pathways. Nevertheless, there are not sufficient data to achieve specific nutritional guidelines. Conclusion: Further research is needed to evaluate the real contribution of EVOO and its phenolic compounds in modulating the IMID-associated inflammatory perturbations, in order to develop appropriate nutritional recommendations.

Download Full-text

Systemic lupus erythematosus complicated by Crohn’s disease: a case report and literature review

BMC Gastroenterology ◽

10.1186/1471-230x-12-174 ◽

2012 ◽

Vol 12 (1) ◽

Cited By ~ 15

Author(s):

Hiroyuki Yamashita ◽

Yo Ueda ◽

Hoshimi Kawaguchi ◽

Akitake Suzuki ◽

Yuko Takahashi ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Crohn’S Disease ◽

Case Report ◽

Crohn's Disease ◽

Literature Review ◽

Lupus Erythematosus ◽

Systemic Lupus

Download Full-text

Systemic Lupus Erythematosus and Crohn's Disease: A Case Report

Reumatología Clínica (English Edition) ◽

10.1016/j.reumae.2011.08.001 ◽

2012 ◽

Vol 8 (3) ◽

pp. 141-142

Author(s):

Antonia María Fernández Rodríguez ◽

Inmaculada Macías Fernández ◽

Natalia Navas García

Keyword(s):

Systemic Lupus Erythematosus ◽

Crohn’S Disease ◽

Case Report ◽

Crohn's Disease ◽

Lupus Erythematosus ◽

Systemic Lupus

Download Full-text

Coexistence of Crohn’s disease in a patient with systemic lupus erythematosus

Rheumatology International ◽

10.1007/s00296-011-2357-1 ◽

2012 ◽

Vol 33 (8) ◽

pp. 2145-2148 ◽

Cited By ~ 3

Author(s):

Konstantinos H. Katsanos ◽

Paraskevi V. Voulgari ◽

Anna Goussia ◽

Panagiotis Oikonomou ◽

Dimitrios K. Christodoulou ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Lupus Erythematosus ◽

Systemic Lupus

Download Full-text

Dose-dependent oral glucocorticoid cardiovascular risk in people with immune-mediated inflammatory diseases

10.1101/2020.03.11.20034157 ◽

2020 ◽

Author(s):

Mar Pujades-Rodriguez ◽

Ann W Morgan ◽

Richard M Cubbon ◽

Jianhua Wu

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Systemic Lupus Erythematosus ◽

Acute Myocardial Infarction ◽

Cardiovascular Risk ◽

Lupus Erythematosus ◽

Inflammatory Diseases ◽

Systemic Lupus ◽

Immune Mediated ◽

Dose Dependent

ABSTRACTBackgroundEvidence for the association between glucocorticoid dose and cardiovascular risk is weak for moderate and low doses. To quantify glucocorticoid dose-dependent cardiovascular risk in people with six immune-mediated inflammatory diseases.Methods and FindingsPopulation-based cohort analysis of medical records from 389 primary care practices contributing data to the UK Clinical Practice Research Datalink, linked to hospital admissions and deaths in 1998-2017. There were 87,794 patients with giant cell arteritis and/or polymyalgia rheumatica (n=25,581), inflammatory bowel disease (n=27,739), rheumatoid arthritis (n=25,324), systemic lupus erythematosus (n=3951), and/or vasculitis (n=5199); and no prior cardiovascular disease (CVD). Mean age was 56 years and 34.1% were men. Median follow-up time was 5.0 years. Time-variant daily and cumulative glucocorticoid prednisolone-equivalent dose-related risks and hazard ratios of first all-cause and type-specific CVD.We found 13,426 (15.3%) people with incident CVD, including 6,013 atrial fibrillation, 7,727 heart failure and 2,809 acute myocardial infarction events. At 1 and 5 years, the cumulative risks of all-cause CVD increased from 1.5% in periods of non-use to 9.1% for a daily prednisolone-equivalent dose of ≥25.0mg, and from 7.6% to 29.9%, respectively. We found strong dose-dependent estimates for all immune-mediated diseases (hazard ratio [HR] for <5.0mg daily dose vs. non-use=1.74, 95%CI 1.64-1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteritis to 2.82 for systemic lupus erythematosus), all cardiovascular outcomes, regardless of disease activity level. The highest estimates were for heart failure and acute myocardial infarction.ConclusionsWe estimated glucocorticoid dose-dependent cardiovascular risk in six immune-mediated diseases. Results highlight the importance of prompt and regular monitoring of cardiovascular risk and use of primary prevention treatment at all glucocorticoid doses.

Download Full-text

Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients

Antibodies ◽

10.3390/antib9020014 ◽

2020 ◽

Vol 9 (2) ◽

pp. 14 ◽

Cited By ~ 1

Author(s):

Roberto Lande ◽

Raffaella Palazzo ◽

Philippe Hammel ◽

Immacolata Pietraforte ◽

Isabelle Surbeck ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Adaptive Responses ◽

Systemic Lupus ◽

Cationic Antimicrobial Peptide ◽

Post Translational Modifications ◽

Immune Mediated ◽

Cationic Amino Acids ◽

B And T Lymphocytes

Human cathelicidin LL37 is a cationic antimicrobial peptide active against bacteria and viruses and exerting immune modulatory functions. LL37 can be also a target of autoreactive B- and T-lymphocytes in autoimmune settings. Irreversible post-translational modifications, such as citrullination and carbamylation, mainly occurring at the level of cationic amino acids arginine and lysine, can affect the inflammatory properties and reduce antibacterial effects. Moreover, these modifications could be implicated in the rupture of immune tolerance to LL37 in chronic conditions such as psoriatic disease and cutaneous lupus (LE)/systemic lupus erythematosus (SLE). Here, we describe the generation and fine specificity of six recombinant antibodies (MRB137–MRB142), produced as a monovalent mouse antibody with the antigen-binding scFv portion fused to a mouse IgG2a Fc, and their ability to recognize either native or citrullinated LL37 (cit-LL37) and not cross-react to carbamylated LL37. By using these antibodies, we detected native LL37 or cit-LL37 in SLE and rheumatoid arthritis (RA) sera, and in LE skin, by ELISA and immunohistochemistry, respectively. Such antibodies represent previously unavailable and useful tools to address relationships between the presence of post-translational modified LL37 and the immune system status (in terms of innate/adaptive responses activation) and the clinical characteristics of patients affected by chronic immune-mediated diseases or infectious diseases.

Download Full-text